Skip to main content
Adocia logo

Adocia — Investor Relations & Filings

Ticker · ADOC ISIN · FR0011184241 LEI · 969500ZL79KYH9PTYP78 PA Real estate activities
Open in API
Filings indexed 826 across all filing types
Latest filing 2016-10-12 Earnings Release
Country FR France
Listing PA ADOC

About Adocia

https://www.adocia.com

Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Quarterly financial report / Third quarter financial report
Earnings Release Classification · 1% confidence The document is explicitly titled '# PRESS RELEASE' and begins by announcing 'Adocia announces third quarter 2016 financial results'. It provides key financial highlights (Revenue, Cash Position) for the third quarter and the nine months ended September 30, 2016, along with management commentary and operational updates. This structure perfectly matches the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results, typically presented as a press release summarizing key figures before the full quarterly report (IR) is filed. It is not a full comprehensive report (IR) or an Annual Report (10-K). 9M 2016
2016-10-12 English
Information financière trimestrielle / Information financière du troisième trimestre
Earnings Release Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and explicitly announces the financial results for the 3rd quarter of 2016, including key figures for revenue and cash position. It contains summarized financial data tables for the 3-month and 9-month periods, management commentary on results, and updates on clinical pipeline events. This structure—a brief announcement highlighting key figures and operational updates for a specific reporting period (quarterly)—is characteristic of an Earnings Release (ER). It is not the full, detailed annual report (10-K) or a comprehensive interim report (IR), but rather the initial public announcement of the period's performance. Q3 2016
2016-10-12 French
Communicated under the obligation to provide permanent information / Other communications
Earnings Release Classification · 1% confidence The document is a press release announcing that the company, Adocia, received the 'EY Global Company Award'. This type of announcement, celebrating an external recognition or award, does not fit neatly into the standard regulatory filing categories (like 10-K, ER, IR) or specific corporate actions (like DIV, CAP, DIRS). It is a general corporate announcement. Given the provided definitions, the most appropriate fallback category for a general, non-standard corporate announcement that doesn't fit elsewhere is 'Regulatory Filings' (RNS), as it serves as a miscellaneous category for such news releases. FY 2016
2016-09-22 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that the company, Adocia, received the 'EY Global Entrepreneur Award' for its region. This is a general corporate announcement regarding an award received, not a mandatory regulatory filing like a 10-K, IR, or ER. It does not fit the specific definitions for financial reports (10-K, IR, ER, FS, IP), management changes (MANG), director dealings (DIRS), or capital actions (CAP, SHA, POS). Since it is a general, non-mandatory corporate announcement that doesn't fit the highly specific categories, the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general announcement category for miscellaneous filings.
2016-09-22 French
Communicated under the obligation to provide permanent information / Other communications
Legal Proceedings Report Classification · 1% confidence The document is explicitly titled '# PRESS RELEASE' and announces the initiation of a new clinical study for a drug candidate (BioChaperone® Combo). It contains forward-looking statements and contact information typical of a corporate announcement intended for immediate public dissemination, rather than a comprehensive regulatory filing like a 10-K or a detailed financial report like an IR. Since it is a press release announcing operational/clinical progress, it does not fit the specific categories like ER (Earnings Release), AR (Audit Report), or CT (Call Transcript). Given the options, this type of announcement, which is a general corporate update often filed with regulators as a miscellaneous filing, is best categorized as a Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides, but as a standard press release, RNS is the most appropriate general regulatory/announcement category when a more specific one isn't available. However, since it details clinical trial initiation and scientific progress, it is a key piece of investor information. Given the options, and recognizing that press releases announcing clinical milestones are often filed broadly, RNS is the fallback. If the document were a detailed presentation, IP would be considered. Since it is a standard press release announcing a major operational event (clinical trial launch), RNS is the most suitable general regulatory announcement code.
2016-09-20 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces the initiation of a new Phase 1b clinical study for a drug candidate (BioChaperone® Combo). It details the study design, objectives, and provides company background and contact information. This type of announcement, detailing operational or clinical progress via a press release format, is typically classified as a general Regulatory Filing (RNS) or sometimes an Earnings Release (ER) if it contained financial results. Since it is purely an operational/clinical update and not a formal financial report (like 10-K or IR) or a management discussion (MDA), and it is not a transcript (CT) or a presentation (IP), the most appropriate general category for a non-standard, non-financial regulatory announcement is RNS (Regulatory Filings), which serves as a broad category for such corporate news releases that don't fit elsewhere. It is not an announcement of a report publication (RPA) because it *is* the substantive announcement itself, not just a notice that a report is available.
2016-09-20 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.